Pinnacle Wealth Planning Services Inc. Buys 470 Shares of Becton, Dickinson and Company $BDX

Pinnacle Wealth Planning Services Inc. boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 42.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,581 shares of the medical instruments supplier’s stock after acquiring an additional 470 shares during the period. Pinnacle Wealth Planning Services Inc.’s holdings in Becton, Dickinson and Company were worth $272,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in BDX. First Eagle Investment Management LLC lifted its holdings in Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock valued at $1,513,421,000 after buying an additional 3,268,478 shares during the period. GQG Partners LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $689,833,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Becton, Dickinson and Company by 24.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock valued at $1,466,613,000 after purchasing an additional 1,670,590 shares during the period. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after purchasing an additional 1,259,750 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in Becton, Dickinson and Company during the first quarter worth approximately $211,097,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.5%

NYSE:BDX opened at $191.34 on Thursday. The firm’s 50 day moving average is $186.74 and its 200 day moving average is $181.98. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The stock has a market capitalization of $54.84 billion, a PE ratio of 34.41, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,249 shares of company stock worth $231,358 in the last 90 days. Company insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Jefferies Financial Group decreased their price target on shares of Becton, Dickinson and Company from $257.00 to $215.00 in a research note on Friday, November 7th. Royal Bank Of Canada cut their price objective on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $203.27.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.